NextPhase’s initial target is psoriasis immediately followed by atopic dermatitis. Our approach is highly differentiated given its efficacy, safety, price positioning, and high likelihood of payor approval. Additionally, it has the potential for being a first-line treatment, and a complement to other existing therapies.

The company’s platform also has potential for other dermatological diseases, such as contact dermatitis, burns (eye burns in particular), post-traumatic and post-surgical complicated wounds, as well as inflammatory autoimmune diseases affecting epithelium. The company will seek to develop these therapies at a future date.